Previous 10 | Next 10 |
The following slide deck was published by Kymera Therapeutics, Inc. in conjunction with this event. For further details see: Kymera Therapeutics (KYMR) Presents At UBS Global Healthcare Virtual Conference - Slideshow
Kymera Therapeutics (KYMR) announces new data demonstrating proof-of-concept for its Pegasus platform, including the identification and characterization of a novel and previously unliganded E3 ligase with restricted expression in healthy tissues while broadly expressed in cancer cells, a...
Novel E3 ligase identified by Kymera’s Whole-Body Atlas is expressed in selected tissues while broadly expressed in cancer cells Novel STAT3 degrader enabled by Pegasus TM platform, and based on identified novel ligase, demonstrates proof-of-concept degradatio...
Kymera Therapeutics ([[KYMR]] +0.1%) presented positive preclinical data showing that IRAK4 degrader KT-474’s was superior compared to a clinically active small molecule IRAK4 kinase inhibitor across a wide variety of immune-inflammatory preclinical in vivo models.KT-474...
New in vivo data demonstrate the broad anti-inflammatory activity of KT-474 and its superiority compared to a clinically active small molecule IRAK4 kinase inhibitor in preclinical immune-inflammatory models KT-474 is in Phase 1 clinical development as a first-in-class oral IRAK...
Kymera Therapeutics (KYMR): Q1 GAAP EPS of -$0.29 misses by $0.14.Revenue of $18.7M (+445.2% Y/Y) misses by $0.35M.Press Release For further details see: Kymera Therapeutics EPS misses by $0.14, misses on revenue
Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 initiated in February; on track to present human proof-of-biology data in 4Q 2021 Oncology degrader programs KT-413 and KT-333 expected to enter clinical development in 2H 2021 WATERTOWN, Mass., May 06, 2021 (GLO...
WATERTOWN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Juliet Williams, PhD,...
WATERTON, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at the upco...
WATERTOWN, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that a late-breaking abstract featuring ...
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
Kymera Therapeutics Inc. Website:
2024-07-12 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 13:30:00 ET Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi , plans to expand the ongoing phase 2 s...
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside ...